Article Details

Tucatinib Plus Trastuzumab Shows "Clinically Meaningful" Activity in HER2+ Metastatic CRC

Retrieved on: 2024-06-18 16:05:03

Tags for this article:

Click the tags to see associated articles and topics

Tucatinib Plus Trastuzumab Shows "Clinically Meaningful" Activity in HER2+ Metastatic CRC. View article details on hiswai:

Excerpt

They could have received fluoropyrimidines, oxaliplatin, irinotecan, and anti-VEGF monoclonal antibodies, but they had received no prior anti-HER2 ...

Article found on: www.cancertherapyadvisor.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo